Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2025
Event: Closing of a best efforts public offering of common stock, pre-funded warrants, and Series F warrants.
Key Financial Metrics
Stockholders' Equity: Exceeds $2.5 million immediately following the completion of the offering.
Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide specific values for these metrics. This report focuses on the capital raise event rather than operational financial performance.
Material Changes
- Capital Structure: The Company completed a public offering involving common stock, pre-funded warrants, and Series F warrants.
- Equity Position: The offering resulted in stockholders' equity rising to a level exceeding $2.5 million.
Outlook, Risks, and Management Commentary
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the offering but does not include specific forward-looking guidance or management discussion within the text of the 8-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt beyond the standard disclosure of the offering event.
Investor Verification Checklist
- Verify the total number of shares and warrants issued in the offering by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the gross proceeds raised from the offering to assess the company's immediate liquidity position.
- Review the terms of the pre-funded warrants and Series F warrants for conversion prices and expiration dates.
- Check the updated share count and potential dilution impact on existing shareholders.